AR053311A1 - Macrolonas - quinolonas amino sustituidas - Google Patents
Macrolonas - quinolonas amino sustituidasInfo
- Publication number
- AR053311A1 AR053311A1 ARP050104704A ARP050104704A AR053311A1 AR 053311 A1 AR053311 A1 AR 053311A1 AR P050104704 A ARP050104704 A AR P050104704A AR P050104704 A ARP050104704 A AR P050104704A AR 053311 A1 AR053311 A1 AR 053311A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- independently
- alkoxy
- group
- Prior art date
Links
- 150000007660 quinolones Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 16
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000004122 cyclic group Chemical group 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 101100294104 Caenorhabditis elegans nhr-34 gene Proteins 0.000 abstract 1
- 229920004011 Macrolon® Polymers 0.000 abstract 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 229940058934 aminoquinoline antimalarials Drugs 0.000 abstract 1
- 150000005010 aminoquinolines Chemical class 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0424959A GB0424959D0 (en) | 2004-11-11 | 2004-11-11 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053311A1 true AR053311A1 (es) | 2007-05-02 |
Family
ID=33523587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050104704A AR053311A1 (es) | 2004-11-11 | 2005-11-09 | Macrolonas - quinolonas amino sustituidas |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7718621B2 (enExample) |
| EP (1) | EP1824870A1 (enExample) |
| JP (1) | JP2008519788A (enExample) |
| KR (1) | KR20070085919A (enExample) |
| CN (1) | CN101098881A (enExample) |
| AR (1) | AR053311A1 (enExample) |
| AU (1) | AU2005303961A1 (enExample) |
| BR (1) | BRPI0517792A (enExample) |
| CA (1) | CA2587413A1 (enExample) |
| GB (1) | GB0424959D0 (enExample) |
| IL (1) | IL182978A0 (enExample) |
| MA (1) | MA29213B1 (enExample) |
| MX (1) | MX2007005776A (enExample) |
| NO (1) | NO20072939L (enExample) |
| PE (1) | PE20061137A1 (enExample) |
| RU (1) | RU2007121581A (enExample) |
| TW (1) | TW200630378A (enExample) |
| WO (1) | WO2006050942A1 (enExample) |
| ZA (1) | ZA200703603B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601695B2 (en) | 2003-03-10 | 2009-10-13 | Optimer Pharmaceuticals, Inc. | Antibacterial agents |
| WO2007054295A1 (en) * | 2005-11-09 | 2007-05-18 | Glaxo Group Limited | New 4*-substituted erythromycin derivative |
| EP1879904A1 (en) * | 2005-05-10 | 2008-01-23 | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. | 4" amino linked macrolides useful for the treatment of microbial infections |
| WO2007054296A1 (en) * | 2005-11-09 | 2007-05-18 | Glaxo Group Limited | Macrolones |
| NZ583878A (en) | 2007-09-14 | 2012-10-26 | Vertex Pharma | Modulators of ABC transporter and cystic fibrosis transmembrane conductance regulator (CFTR) |
| AU2008316830B2 (en) | 2007-10-25 | 2016-03-17 | Cempra Pharmaceuticals, Inc. | Process for the preparation of macrolide antibacterial agents |
| TW200946109A (en) * | 2008-05-09 | 2009-11-16 | Enanta Pharm Inc | Anti-bacterial activity of 9-hydroxy derivatives 6, 11-bicyclolides |
| CN107854477A (zh) | 2008-10-24 | 2018-03-30 | 森普拉制药公司 | 使用含三唑的大环内酯治疗抗性疾病的方法 |
| US9937194B1 (en) | 2009-06-12 | 2018-04-10 | Cempra Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory diseases |
| US9480679B2 (en) | 2009-09-10 | 2016-11-01 | Cempra Pharmaceuticals, Inc. | Methods for treating malaria, tuberculosis and MAC diseases |
| BR112012029586A2 (pt) * | 2010-05-20 | 2016-08-02 | Cempra Pharmaceuticals Inc | processos para preparar macrolídeos e cetolídeos e intermediários dos mesmos |
| KR20130120458A (ko) | 2010-09-10 | 2013-11-04 | 셈프라 파마슈티컬스, 인크. | 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드 |
| WO2013148891A1 (en) | 2012-03-27 | 2013-10-03 | Cempra Pharmaceuticals, Inc. | Parenteral formulations for administering macrolide antibiotics |
| WO2014152326A1 (en) | 2013-03-14 | 2014-09-25 | Cempra Pharmaceuticals, Inc. | Methods for treating respiratory diseases and formulations therefor |
| AU2014233240B2 (en) | 2013-03-15 | 2018-08-09 | Cempra Pharmaceuticals, Inc. | Convergent processes for preparing macrolide antibacterial agents |
| CN106589023A (zh) * | 2016-11-22 | 2017-04-26 | 宜昌东阳光药业股份有限公司 | 一种罗红霉素杂质及其合成方法 |
| CN110475777B (zh) | 2017-03-30 | 2022-04-15 | 豪夫迈·罗氏有限公司 | 用于治疗和预防细菌感染的新吡啶并[2,3-b]吲哚化合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2808070A1 (de) * | 1978-02-24 | 1979-08-30 | Bayer Ag | Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten |
| GB0127349D0 (en) | 2001-11-14 | 2002-01-02 | Glaxo Group Ltd | Macrolides |
| GB0225384D0 (en) | 2002-10-31 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
-
2004
- 2004-11-11 GB GB0424959A patent/GB0424959D0/en not_active Ceased
-
2005
- 2005-11-09 AU AU2005303961A patent/AU2005303961A1/en not_active Abandoned
- 2005-11-09 CA CA002587413A patent/CA2587413A1/en not_active Abandoned
- 2005-11-09 JP JP2007540573A patent/JP2008519788A/ja not_active Withdrawn
- 2005-11-09 RU RU2007121581/04A patent/RU2007121581A/ru not_active Application Discontinuation
- 2005-11-09 BR BRPI0517792-8A patent/BRPI0517792A/pt not_active IP Right Cessation
- 2005-11-09 MX MX2007005776A patent/MX2007005776A/es unknown
- 2005-11-09 WO PCT/EP2005/012038 patent/WO2006050942A1/en not_active Ceased
- 2005-11-09 CN CNA2005800463765A patent/CN101098881A/zh active Pending
- 2005-11-09 US US11/719,004 patent/US7718621B2/en not_active Expired - Fee Related
- 2005-11-09 KR KR1020077012942A patent/KR20070085919A/ko not_active Withdrawn
- 2005-11-09 EP EP05801894A patent/EP1824870A1/en not_active Withdrawn
- 2005-11-09 TW TW094139277A patent/TW200630378A/zh unknown
- 2005-11-09 AR ARP050104704A patent/AR053311A1/es not_active Application Discontinuation
- 2005-11-09 PE PE2005001311A patent/PE20061137A1/es not_active Application Discontinuation
-
2006
- 2006-11-07 US US12/093,145 patent/US20080269146A1/en not_active Abandoned
-
2007
- 2007-05-03 IL IL182978A patent/IL182978A0/en unknown
- 2007-05-04 ZA ZA200703603A patent/ZA200703603B/en unknown
- 2007-05-22 MA MA29930A patent/MA29213B1/fr unknown
- 2007-06-08 NO NO20072939A patent/NO20072939L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20080090773A1 (en) | 2008-04-17 |
| MX2007005776A (es) | 2007-07-16 |
| PE20061137A1 (es) | 2006-12-13 |
| TW200630378A (en) | 2006-09-01 |
| EP1824870A1 (en) | 2007-08-29 |
| US20080269146A1 (en) | 2008-10-30 |
| NO20072939L (no) | 2007-08-08 |
| MA29213B1 (fr) | 2008-02-01 |
| KR20070085919A (ko) | 2007-08-27 |
| RU2007121581A (ru) | 2008-12-20 |
| US7718621B2 (en) | 2010-05-18 |
| CN101098881A (zh) | 2008-01-02 |
| GB0424959D0 (en) | 2004-12-15 |
| AU2005303961A1 (en) | 2006-05-18 |
| JP2008519788A (ja) | 2008-06-12 |
| IL182978A0 (en) | 2007-08-19 |
| CA2587413A1 (en) | 2006-05-18 |
| WO2006050942A1 (en) | 2006-05-18 |
| ZA200703603B (en) | 2008-07-30 |
| BRPI0517792A (pt) | 2008-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR086094A1 (es) | Derivados nucleosidicos 2’-azido sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales por vhc | |
| CO5290258A1 (es) | Derivados de fenilheteroalquilaminas, proceso para su prepracion y composiciones farmaceuticas que contienen dichos derivados | |
| AR086095A1 (es) | Derivados de nucleosidos 2’-sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| AR086096A1 (es) | Derivados de nucleosidos 2’-ciano sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| AR039659A1 (es) | Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasa | |
| AR033306A1 (es) | Compuestos | |
| AR063804A1 (es) | Compuestos de azoniabiciclo[2.2.2]octano | |
| AR038240A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
| AR044401A1 (es) | Compuestos derivados de quinoleina, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de medicamentos. | |
| AR035235A1 (es) | Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| AR031613A1 (es) | Derivados de piridina, un medicamento, una composicion farmaceutica, un inhibidor de la quinasa betaikappab, un medicamento anti-inflamatorio, un inmunosupresor, un medicamento para la isquemia, un medicamento anti-tumoral y el uso de dichos derivados para la preparacion de un medicamento | |
| AR082994A1 (es) | Derivados de pirazina como bloqueadores del canal epitelial de sodio | |
| AR045389A1 (es) | Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido | |
| CA2487542A1 (en) | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | |
| AR067443A1 (es) | Derivados heterociclicos de n-benziloxazolidinonas potenciadores de receptores de glutamato mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos del sistema nervioso central | |
| AR044514A1 (es) | Acidos carboxilicos alfa sustituidos como moduladores ppar | |
| AR073687A1 (es) | Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras. | |
| AR044006A1 (es) | Compuesto de fenilpiperidinilo, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para la preparacion de dicho compuesto | |
| AR047056A1 (es) | Derivados de pirimidinas condensadas. composiciones farmacéuticas | |
| AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
| AR064414A1 (es) | Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que | |
| AR044304A1 (es) | Compuesto de macrolido de 14 y 15 miembros sustituido en la posicion 4'', procedimiento para la preparacion del mismo, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |